Appropriate Duration of First-line Immunotherapy for Advanced NSCLC and Predictive Factors.
Research clarifies how long patients need immunotherapy for advanced lung cancer and identifies who benefits most, personalizing treatment plans.
This review examines the optimal duration of first-line immunotherapy for advanced NSCLC and identifies predictive factors. It addresses a practical clinical question relevant to treatment optimization.
What the study was
- Study design
- Review
- Population
- Advanced NSCLC patients on first-line immunotherapy
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Chinese Journal of Lung Cancer
Why it surfaced
Clinically relevant question on immunotherapy duration. Review format in Chinese-language journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.